Rankin Aubrey
- SEC CIK
- 0001818576
No open-market purchases or sales filed in the past year.
Current role at each company
- RVNC Revance Therapeutics, Inc.Directoras of Mar 17, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Rankin Aubrey as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 6, 2021 (view filing) | Dec 3 | 3 days | Rankin AubreyPresident, Innovation & Tech | PPurchase | +30.0K | $14.43 | +$432.9K | +45.8%95.5K after | |
| Aug 17, 2021 (view filing) | Aug 16 | 1 day | Rankin AubreyPresident, Innovation & Tech | SSale | −9.36K | $26.34 | −$246.6K | −12.5%65.5K after | |
| Jul 30, 2021 (view filing) | Jul 28 | 2 days | Rankin AubreyPresident, Innovation & Tech | SSale | −54.3K | $30.06 | −$1.63M | −26.0%154.3K after | 2 lots |
| Jul 28, 2021 (view filing) | Jul 26 | 2 days | Rankin AubreyPresident, Innovation & Tech | SSale | −55.4K | $29.72 | −$1.65M | −13.5%355.9K after |